<DOC>
	<DOCNO>NCT02690883</DOCNO>
	<brief_summary>This multi-center , randomize , parallel study evaluate effect exenatide 24h-UAER patient diabetic nephropathy . Screening make select eligible participant intervention . The trial include 2-week run-in period stable dos glargine plus lispro insulin 24-week treatment period . After run-in period , patient randomly assign one two group antihyperglycaemic therapy total 24-weeks : glargine plus exenatide continued glargine plus lispro insulin . The treatment exenatide initiate 5ug bid , uptitrated 10 ug bid 4 week maintain 10ug bid completion study . Lispro insulin initially treat accord insulin dosage previous antihyperglycaemic therapy , titrate 4-week interval reach target fast blood glucose ( FPG ) .</brief_summary>
	<brief_title>Effect Exenatide 24h-UAER Patients With Diabetic Nephropathy</brief_title>
	<detailed_description>Objective : To evaluate effect exenatide 24-UAER patient diabetic nephropathy Hypothesis : Compared glargine plus lispro group , 24 week , glargine plus exenatide group : 1 ) take significant reduction 24h-UAER ; 2 ) take reduction ACR ; 3 ) take weight loss , blood pressure reduction ; 4 ) take low hypoglycemia incidence less insulin dosage . Primary endpoint： The proportion reduction 24h-UAER ( urinary albumin excretion rate ) Secondary endpoints： 24h-UAER 24 week ; rate urinary albumin creatinine ratio ( ACR ) change 24 week ; HbA1c , FPG , PPG , weight , BP Treatment duration： 24weeks Patient/Sites： 90 patient / 3 site Timeline ( best case ) ： Planed duration recruitment period : 6 month Planed date first screen : 1 October 2015 Planed completion last subject : 1 March 2017 Planned completion clinical trial report : 30 October 2017</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Diabetic Nephropathies</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<mesh_term>Insulin Lispro</mesh_term>
	<criteria>1 . Provision inform consent prior study specific procedure . 2 . Diagnosed type 2 diabetes HbA1c ≥ 7.0 % ≤ 10.0 % screening ( result valid seven day ) . 3 . Men woman ( nonpregnant use medically approve birthcontrol method ) age 18 70 screening . 4 . Body mass index ( BMI ) ≥18 ≤35 kg/m2 . 5 . Blood Pressure ( BP ) ≥ 90/60mmHg ≤160/100mmHg . 6.24h urinary albumin excretion rate ( UAE ) &gt; 0.3g/24h 3 month treatment several hypoglycemic agent ( sulphonylureas , metformin , AGinhibitor , meglitinides insulin ) , ACEI/ARB salt restriction ( result valid seven day ) . 7.GFR &gt; 45ml/min ( result valid seven day ) . 1．Women pregnant , intend become pregnant study period , currently lactate female , woman childbearing potential use highly effective , medically approve birth control method . 2 . Diagnosis history : 1 . Type 1 diabetes mellitus , diabetes result pancreatic injury secondary form diabetes , eg , acromegaly Cushing 's syndrome . 2 . Acute metabolic diabetic complication ketoacidosis hyperosmolar coma within past 6 month . 3 . Previous treatment Thiazolidinediones ( TZDs ) , dipeptidyl peptidase4 ( DPP4 ) inhibitor GLP1 receptor agonist within past one year . 4 . History hypersensitivity reaction ( e.g. , anaphylaxis , angioedema , exfoliative skin condition ) exenatide . 5 . Blood amylase and/or lipase &gt; 2 time upper limit normal ( ULN ) laboratory range . 6 . Hyperkalemia ( K+ &gt; 5.5mmol/L ) . 7. eGFR ＜45ml/min/1.73m2 . 8 . Patients without diabetic retinopathy . 9 . Triglycerides ( fast ) &gt; 4.5 mmol/L ( 400 mg/dL ) screening within 4 week prior screen ( local laboratory ) . 10 . Patients clinically apparent liver disease characterize ALT AST &gt; 3ULN confirm two consecutive measurement ( local laboratory ) within 4 week prior screen period . 11 . Significant cardiovascular history within past 3 month prior screen define : myocardial infarction , coronary angioplasty bypass graft ( ) , valvular disease repair , unstable angina pectoris , transient ischemic attack , cerebrovascular accident . 12 . Congestive heart failure define New York Heart Association ( NYHA ) class III IV . 13 . History chronic pancreatitis idiopathic acute pancreatitis . 14 . History medullary thyroid carcinoma .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>